Topic Systematic review of risk factors for nonadherence and nonpersistence to intravitreal
anti–vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related …

has multiple small lipid deposits called drusen (< 63 μm) and a smaller number of medium
drusen (63-125 μm) under the retina, or mild pigmentation abnormalities of the retinal …

Intravitreal injections and implants are used to deliver drugs to the retina because
therapeutic levels of these medications cannot be provided by topical administration (ie eye …

Purpose The coronavirus pandemic has prompted unprecedented delays to treatment with
anti-VEGF intravitreal injections due to the need to reduce hospital attendances and …

There is increasing information available about the effects of the SARS-CoV-2 virus on the
systemic and ocular health of patients, as well as the effects of delayed health care. This …

Importance Visit adherence has been shown to play a significant role in patient health
outcomes. The effect of missing visits on visual acuity (VA) in individuals with neovascular …

The advent of anti-vascular endothelial growth factor (VEGF) agents has revolutionized the
treatment of retinal neovascular diseases including neovascular age-related macular …

Purpose To analyze and compare loss to follow-up (LTFU) rates between patients with
diabetic retinopathy (DR) and those with neovascular age-related macular degeneration …

Purpose To determine the incidence of being lost to follow-up (LTFU) and nonpersistence in
patients with neovascular age-related macular degeneration (AMD) treated with anti–VEGF …

Purpose This study characterizes the association of risk factors including race, ethnicity, and
insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in …